Dr. Sen explained that ITP is a condition where the body’s platelet count is low (thrombocytopenia), leading to spots and bruises on the body (purpura). It is called “idiopathic” because the cause is unknown. The disease typically presents in an otherwise healthy child who suddenly develops these spots. While many cases resolve on their own without treatment, intervention is needed for those with very low platelet counts or persistent symptoms.

Evolution of ITP Treatment

Historically, the first line of treatment for ITP has been intravenous immunoglobulin (IVIG), a blood product that blocks antibody centers, and steroids. While effective, steroids have significant side effects, including mood swings, weight gain, and increased risk of infection, making long-term use unsustainable.

A new class of agents, known as TPO (thrombopoietin) agonists, has brought about a significant change in ITP treatment. These drugs, such as romiplostim and eltrombopag, work by increasing the body’s platelet count. Dr. Sen noted that this has been a “paradigm change,” offering a new option for patients who do not respond to or cannot tolerate the side effects of traditional therapies.

Future of ITP Treatment

Looking ahead, Dr. Sen expressed excitement about the potential of CAR T-cell therapy for ITP. While currently used for certain types of leukemia, CAR T-cells target B-cells, which are also responsible for producing the antibodies that cause ITP. Dr. Sen believes that in the future, a modified CAR T-cell therapy could offer a one-shot, curative treatment for chronic ITP, potentially eliminating the need for long-term medication.